Marfan's syndrome cost-effectiveness of therapy

Marfan's syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Differentiating Marfan's Syndrome from other Diseases
Epidemiology and Demographics
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Marfan's syndrome cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Marfan's syndrome cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Marfan's syndrome cost-effectiveness of therapy
on Marfan's syndrome cost-effectiveness of therapy
Marfan's syndrome cost-effectiveness of therapy in the news
Blogs on Marfan's syndrome cost-effectiveness of therapy
Directions to Hospitals Treating Marfan's syndrome
Risk calculators and risk factors for Marfan's syndrome cost-effectiveness of therapy

Editors-In-Chief: William James Gibson, C. Michael Gibson, M.S., M.D.

Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [1] ; Assistant Editor-In-Chief: Cassandra Abueg, M.P.H. [2]

Cost Effectiveness

Currently, laboratories offer complete sequencing of the 65 exon FBN1 gene for approximately $1700.00 . The high costs of these diagnostics have delayed the widespread use of molecular diagnostics in the approach to patients suspected of Marfan syndrome. Increasingly less expensive sequencing technologies promise to increase reliance on individual genetic data for diagnosis in the future.